GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Cyclically Adjusted Revenue per Share

DexCom (DexCom) Cyclically Adjusted Revenue per Share : $4.58 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is DexCom Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DexCom's adjusted revenue per share for the three months ended in Mar. 2024 was $2.210. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.58 for the trailing ten years ended in Mar. 2024.

During the past 12 months, DexCom's average Cyclically Adjusted Revenue Growth Rate was 23.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 30.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 32.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of DexCom was 39.20% per year. The lowest was 30.30% per year. And the median was 35.80% per year.

As of today (2024-04-29), DexCom's current stock price is $125.81. DexCom's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $4.58. DexCom's Cyclically Adjusted PS Ratio of today is 27.47.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 71.43. The lowest was 15.47. And the median was 35.67.


DexCom Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for DexCom's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Cyclically Adjusted Revenue per Share Chart

DexCom Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.49 1.98 2.67 3.48 4.38

DexCom Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 3.93 4.17 4.38 4.58

Competitive Comparison of DexCom's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, DexCom's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexCom's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DexCom's Cyclically Adjusted PS Ratio falls into.



DexCom Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DexCom's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.21/129.4194*129.4194
=2.210

Current CPI (Mar. 2024) = 129.4194.

DexCom Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.195 100.560 0.251
201409 0.227 100.428 0.293
201412 0.275 99.070 0.359
201503 0.234 99.621 0.304
201506 0.293 100.684 0.377
201509 0.327 100.392 0.422
201512 0.401 99.792 0.520
201603 0.354 100.470 0.456
201606 0.411 101.688 0.523
201609 0.442 101.861 0.562
201612 0.507 101.863 0.644
201703 0.418 102.862 0.526
201706 0.488 103.349 0.611
201709 0.532 104.136 0.661
201712 0.636 104.011 0.791
201803 0.528 105.290 0.649
201806 0.678 106.317 0.825
201809 0.738 106.507 0.897
201812 0.952 105.998 1.162
201903 0.777 107.251 0.938
201906 0.923 108.070 1.105
201909 1.071 108.329 1.280
201912 1.249 108.420 1.491
202003 1.076 108.902 1.279
202006 1.164 108.767 1.385
202009 1.259 109.815 1.484
202012 1.432 109.897 1.686
202103 1.207 111.754 1.398
202106 1.393 114.631 1.573
202109 1.511 115.734 1.690
202112 1.618 117.630 1.780
202203 1.467 121.301 1.565
202206 1.652 125.017 1.710
202209 1.807 125.227 1.868
202212 1.914 125.222 1.978
202303 1.772 127.348 1.801
202306 2.019 128.729 2.030
202309 2.284 129.860 2.276
202312 2.480 129.419 2.480
202403 2.210 129.419 2.210

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


DexCom  (NAS:DXCM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

DexCom's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=125.81/4.58
=27.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DexCom was 71.43. The lowest was 15.47. And the median was 35.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DexCom Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of DexCom's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


DexCom (DexCom) Business Description

Industry
Address
6340 Sequence Drive, San Diego, CA, USA, 92121
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Executives
Sadie Stern officer: Chief Human Resources Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman director
Kevin R Sayer director
Jereme M Sylvain officer: SVP, Finance & CAO 6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach officer: SVP, Research & Development 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos director 754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown officer: EVP, Chief Legal Officer 6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli officer: Vice President Legal Affairs 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan officer: EVP Chief Technology Officer C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan officer: EVP Operations 1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller director TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan officer: * 6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj officer: SVP Information Technology 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn officer: EVP, Global Revenue 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

DexCom (DexCom) Headlines

From GuruFocus

Q4 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Dexcom Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024